Literature DB >> 26861600

The use of ipilimumab in patients with rheumatoid arthritis and metastatic melanoma.

B Lee1, A Wong2, D Kee2, P Neeson3, M Shackleton4, G McArthur5, S Sandhu6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26861600     DOI： 10.1093/annonc/mdw056

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  24 in total

Review 1.  Cancer immunotherapy in patients with preexisting autoimmune disorders.

Authors:  Marco Donia; Magnus Pedersen; Inge Marie Svane
Journal:  Semin Immunopathol       Date:  2016-10-11       Impact factor: 9.623

Review 2.  Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer.

Authors:  Grainne M O'Kane; Catherine Labbé; Mark K Doherty; Kelvin Young; Hamzeh Albaba; Natasha B Leighl
Journal:  Oncologist       Date:  2016-08-17

Review 3.  Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases.

Authors:  Alice Tison; Soizic Garaud; Laurent Chiche; Divi Cornec; Marie Kostine
Journal:  Nat Rev Rheumatol       Date:  2022-10-05       Impact factor: 32.286

Review 4.  Immune checkpoint inhibitor-induced musculoskeletal manifestations.

Authors:  Foteini Angelopoulou; Dimitrios Bogdanos; Theodoros Dimitroulas; Lazaros Sakkas; Dimitrios Daoussis
Journal:  Rheumatol Int       Date:  2020-08-02       Impact factor: 2.631

5.  Management of advanced kidney cancer: Canadian Kidney Cancer Forum (CKCF) consensus update 2017.

Authors:  M Neil Reaume; Naveen S Basappa; Lori Wood; Anil Kapoor; Georg A Bjarnason; Normand Blais; Rodney H Breau; Christina Canil; Patrick Cheung; Henry J Conter; Sebastien J Hotte; Claudio Jeldres; Michael A S Jewett; Pierre I Karakiewicz; Christian Kollmannsberger; Francois Patenaude; Alan So; Denis Soulières; Peter Venner; Phillippe Violette; Pawel Zalewski; Heather Chappell; Scott A North
Journal:  Can Urol Assoc J       Date:  2017-10       Impact factor: 1.862

Review 6.  Immunotherapy use outside clinical trial populations: never say never?

Authors:  K Rzeniewicz; J Larkin; A M Menzies; S Turajlic
Journal:  Ann Oncol       Date:  2021-03-24       Impact factor: 51.769

Review 7.  Immunotherapy Use in Patients With Lung Cancer and Comorbidities.

Authors:  Mitchell S von Itzstein; Amrit S Gonugunta; Helen G Mayo; John D Minna; David E Gerber
Journal:  Cancer J       Date:  2020 Nov/Dec       Impact factor: 2.074

8.  Safety of immune checkpoint inhibitors in patients with cancer and pre-existing autoimmune disease.

Authors:  Swetha Alexander; Umang Swami; Aneet Kaur; Yubo Gao; Munazza Fatima; Meredith M Ginn; Jill E Stein; Petros Grivas; Yousef Zakharia; Namrata Singh
Journal:  Ann Transl Med       Date:  2021-06

Review 9.  Advances in the management of pancreatic ductal adenocarcinoma.

Authors:  Grainne M O'Kane; Farah Ladak; Steven Gallinger
Journal:  CMAJ       Date:  2021-06-07       Impact factor: 8.262

10.  Risk of Toxicity After Initiating Immune Checkpoint Inhibitor Treatment in Patients With Rheumatoid Arthritis.

Authors:  Elizaveta Efuni; Samuel Cytryn; Patrick Boland; Timothy B Niewold; Anna Pavlick; Jeffrey Weber; Sabina Sandigursky
Journal:  J Clin Rheumatol       Date:  2021-10-01       Impact factor: 3.902
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.